Priority Review Granted to Novel Pneumococcal Conjugate Vaccine V114
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.
The V114 vaccine candidate consists of pneumococcal polysaccharides from 15 serotypes, including serotypes 22F and 33F, which are associated with invasive pneumococcal disease.
Risk for related mortality increased with urinary cadmium in the 80th versus the 20th percentile in whole population, never smokers in NHANES-III
Researchers investigated the effects of ILI on pneumococcal carriage in community-dwelling older adults.
The incidence of invasive pneumococcal disease (IPD) in adults has decreased considerably over the past few decades.
Study authors described the prescribing patterns in children with community-acquired pneumonia, and assessed the relationship between narrow-spectrum antibiotics, broad-spectrum antibiotics, and macrolides with clinical outcomes.
The effect of appropriate antimicrobial therapy on 14-day mortality in patients severely ill with Acinetobacter baumannii bacteremic pneumonia was assessed, taking risk factors, patient demographics, and clinical characteristics into account.
Although hypercoagulability has been reported in critically ill patients with COVID-19, results from a small study revealed that these patients did not have a higher prevalence of pulmonary embolism compared to patients without COVID-19.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
How should physicians be discussing influenza and pneumococcal vaccines with patients amidst the continuing COVID-19 pandemic?
Approximately 7% of pneumonia cases acquired in the intensive care unit can be classified as Staphylococcus aureus intensive care unit pneumonia.